Efficacy and Safety of Transvenous Lead Extraction at the Time of Upgrade from Pacemakers to Cardioverter-Defibrillators and Cardiac Resynchronization Therapy

被引:1
|
作者
Stefanczyk, Pawel [1 ]
Nowosielecka, Dorota [1 ,2 ]
Polewczyk, Anna [3 ,4 ]
Jachec, Wojciech [5 ]
Glowniak, Andrzej [6 ]
Kosior, Jaroslaw [7 ]
Kutarski, Andrzej [6 ]
机构
[1] Pope John Paul II Prov Hosp, Dept Cardiol, PL-22400 Zamosc, Poland
[2] Pope John Paul II Prov Hosp, Dept Cardiac Surg, PL-22400 Zamosc, Poland
[3] Jan Kochanowski Univ, Inst Med Sci, Dept Physiol Pathophysiol & Clin Immunol, PL-25369 Kielce, Poland
[4] Swietokrzyskie Cardiol Ctr, Dept Cardiac Surg, PL-25736 Kielce, Poland
[5] Silesian Med Univ Katowice, Fac Med Sci Zabrze, Dept Cardiol 2, PL-41800 Zabrze, Poland
[6] Med Univ, Dept Cardiol, PL-20059 Lublin, Poland
[7] Masovian Specialist Hosp, Dept Cardiol, PL-26617 Radom, Poland
关键词
device upgrade; transvenous lead extraction; prophylaxis of lead abandonment; restoration of venous access; EXPERT CONSENSUS STATEMENT; VENOUS OCCLUSION; DEVICE UPGRADE; IMPLANTATION;
D O I
10.3390/ijerph20010291
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Upgrading from pacemakers to ICDs and CRTs is a difficult procedure, and often, transvenous lead extraction (TLE) is necessary for venous access. TLE is considered riskier in patients with multiple diseases. We aimed to assess the complexity, risk, and outcome of TLE among CRT and ICD candidates. Methods: We analyzed clinical data from 2408 patients undergoing TLE between 2006 and 2021. There were 138 patients upgraded to CRT-D, 33 patients upgraded to CRT-P and 89 individuals upgraded to ICD versus 2148 patients undergoing TLE for other non-infectious indications. Results: The need for an upgrade was the leading indication for TLE in only 36-66% of patients. In 42.0-57.6% of patients, the upgrade procedure could be successfully done only after reestablishing access to the occluded vein. All leads were extracted in 68.1-76.4% of patients, functional leads were retained in 20.2-31.9%, non-functional leads were left in place in 0.0-1.1%, and non-functional superfluous leads were extracted in 3.6-8.4%. The long-term survival rate of patients in the CRT-upgrade group was lower (63.8%) than in the non-upgrade group (75.2%). Conclusions: Upgrading a patient from an existing pacemaker to an ICD/CRT is feasible in 100% of cases, provided that TLE is performed for venous access. Major complications of TLE at the time of device upgrade are rare and, if present do not result in death.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Service life of implantable cardioverter-defibrillators for cardiac resynchronization therapy: an analysis of determinants in current clinical practice
    Landolina, M.
    Curnis, A.
    Morani, G.
    Vado, A.
    Ammendola, E.
    D'Onofrio, A.
    Stabile, G.
    Crosato, M.
    Gasparini, M.
    EUROPEAN HEART JOURNAL, 2015, 36 : 390 - 390
  • [22] Remote monitoring of pacemakers and implantable cardioverter-defibrillators, safety aspects and study in cardiac implant patients on EMF exposure
    Plawiak-Mowna, Anna
    Krawczyk, Andrzej
    PRZEGLAD ELEKTROTECHNICZNY, 2011, 87 (12B): : 137 - 140
  • [23] Safety and Efficacy of Lead Extraction at Time of Device Upgrade
    Power, John R.
    Patel, Kavisha
    Jacobs, Kathleen
    Pollema, Travis
    Ho, Gordon
    Birgersdotter-Green, Ulrika
    CIRCULATION, 2023, 148
  • [24] IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS AND CARDIAC RESYNCHRONIZATION THERAPY DEMANDS IN RUSSIAN FEDERATION: CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY
    Stavtseva, Y.
    Villevalde, S.
    Vorobiev, A.
    Sveshnikov, A.
    Kobalaba, Z.
    JOURNAL OF HYPERTENSION, 2015, 33 : E397 - E397
  • [25] Exercise Interventions in Patients With Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy A SYSTEMATIC REVIEW AND META-ANALYSIS
    Steinhaus, Daniel A.
    Lubitz, Steven A.
    Noseworthy, Peter A.
    Kramer, Daniel B.
    JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION, 2019, 39 (05) : 308 - 317
  • [26] Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA
    Boriani, Giuseppe
    Merino, Jose
    Wright, David J.
    Gadler, Fredrik
    Schaer, Beat
    Landolina, Maurizio
    EUROPACE, 2018, 20 (12): : 1882 - 1897
  • [27] The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives
    Landolina, Maurizio
    Morani, Giovanni
    Curnis, Antonio
    Vado, Antonello
    D'Onofrio, Antonio
    Bianchi, Valter
    Stabile, Giuseppe
    Crosato, Martino
    Petracci, Barbara
    Ceriotti, Carlo
    Bontempi, Luca
    Morosato, Martina
    Ballari, Gian Paolo
    Gasparini, Maurizio
    EUROPACE, 2017, 19 (08): : 1349 - 1356
  • [28] SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR AFTER TRANSVENOUS LEAD EXTRACTION: SAFETY, EFFICACY AND OUTCOME
    Pittorru, Raimondo
    Giacomin, Enrico
    Migliore, Federico
    Falzone, Pasquale
    Dall'aglio, Pietro Bernardo
    De Lazzari, Manuel
    Vianello, Riccardo
    Iliceto, Sabino
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [29] Subcutaneous implantable cardioverter defibrillator after transvenous lead extraction: safety, efficacy and outcome
    Giacomin, Enrico
    Falzone, Pasquale Valerio
    Dall'Aglio, Pietro Bernardo
    Pittorru, Raimondo
    De Lazzari, Manuel
    Vianello, Riccardo
    Bertaglia, Emanuele
    Tarzia, Vincenzo
    Iliceto, Sabino
    Gerosa, Gino
    Migliore, Federico
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2022,
  • [30] Electromagnetic interference with cardiac pacemakers and implantable cardioverter-defibrillators from low-frequency electromagnetic fields in vivo
    Tiikkaja, Maria
    Aro, Aapo L.
    Alanko, Tommi
    Lindholm, Harri
    Sistonen, Heli
    Hartikainen, Juha E. K.
    Toivonen, Lauri
    Juutilainen, Jukka
    Hietanen, Maila
    EUROPACE, 2013, 15 (03): : 388 - 394